182 related articles for article (PubMed ID: 25753440)
41. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].
Xu Y; Bai QM; Yang F; Zhu XL; Lu YM; Zhang J; Yang WT; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):545-9. PubMed ID: 27510780
[TBL] [Abstract][Full Text] [Related]
42. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
Moeder CB; Giltnane JM; Harigopal M; Molinaro A; Robinson A; Gelmon K; Huntsman D; Camp RL; Rimm DL; ;
J Clin Oncol; 2007 Dec; 25(34):5418-25. PubMed ID: 18048824
[TBL] [Abstract][Full Text] [Related]
43. Impact of Consensus Guidelines by the Society of Surgical Oncology and the American Society for Radiation Oncology on Margins for Breast-Conserving Surgery in Stages 1 and 2 Invasive Breast Cancer.
Chung A; Gangi A; Amersi F; Bose S; Zhang X; Giuliano A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S422-7. PubMed ID: 26310280
[TBL] [Abstract][Full Text] [Related]
44. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
Hammond ME; Hayes DF; Wolff AC
J Clin Oncol; 2011 May; 29(15):e458. PubMed ID: 21502545
[No Abstract] [Full Text] [Related]
45. Utility of cytopathological specimens and an automated image analysis for the evaluation of HER2 status and intratumor heterogeneity in breast carcinoma.
Arihiro K; Oda M; Ogawa K; Kaneko Y; Shimizu T; Tanaka Y; Marubashi Y; Ishida K; Takai C; Taoka C; Kimura S; Shiroma N
Pathol Res Pract; 2016 Dec; 212(12):1126-1132. PubMed ID: 27712974
[TBL] [Abstract][Full Text] [Related]
46. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
[TBL] [Abstract][Full Text] [Related]
47. Ki67 in breast cancer: a useful prognostic marker?
Caldarella A; Crocetti E; Paci E
Ann Oncol; 2014 Feb; 25(2):542. PubMed ID: 24412822
[No Abstract] [Full Text] [Related]
48. Reply to Ki67 in breast cancer: a useful prognostic marker!
Denkert C; von Minckwitz G
Ann Oncol; 2014 Feb; 25(2):542-3. PubMed ID: 24431345
[No Abstract] [Full Text] [Related]
49. Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
Qian XL; Wen HY; Yang YL; Gu F; Guo XJ; Liu FF; Zhang L; Zhang XM; Fu L
Breast Cancer Res Treat; 2016 Aug; 159(1):31-9. PubMed ID: 27455837
[TBL] [Abstract][Full Text] [Related]
50. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
51. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ismaila N; Ajani JA
J Oncol Pract; 2017 Jan; 13(1):53-57. PubMed ID: 27907277
[No Abstract] [Full Text] [Related]
52. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
53. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
54. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines.
Stoffel EM; Mangu PB; Limburg PJ; ;
J Oncol Pract; 2015 May; 11(3):e437-41. PubMed ID: 25829526
[No Abstract] [Full Text] [Related]
55. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
56. Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
Huang Y; Burns DJ; Rich BE; MacNeil IA; Dandapat A; Soltani SM; Myhre S; Sullivan BF; Lange CA; Furcht LT; Laing LG
BMC Cancer; 2017 Mar; 17(1):199. PubMed ID: 28302091
[TBL] [Abstract][Full Text] [Related]
57. The assessment of HER2 status in breast cancer: the past, the present, and the future.
Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
[TBL] [Abstract][Full Text] [Related]
58. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.
Yamauchi H; Stearns V; Hayes DF
J Clin Oncol; 2001 Apr; 19(8):2334-56. PubMed ID: 11304787
[TBL] [Abstract][Full Text] [Related]
59. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
[TBL] [Abstract][Full Text] [Related]
60. [HER2 testing in gastric cancer - results of a German expert meeting].
Lordick F; Al-Batran SE; Hofheinz RD; Lorenzen S; Thuss-Patience P; Baretton GB; Dietel M; Gaiser T; Kirchner T; Kreipe HH; Quaas A; Röcken C; Rüschoff J; Tannapfel A
Z Gastroenterol; 2016 Aug; 54(8):791-6. PubMed ID: 27529529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
